There is a group of providers who oppose compounded HRT medications on principle. Their argument sounds evidence-based. Standardization. Regulation. Studies. It holds up until you look at what they are actually prescribing.

In this episode, Nico Misleh, MSN FNP-C, walks through two clinical examples that expose the internal contradiction: the Androgel problem, in which providers who oppose compounding are instructing female patients to eyeball a fraction of a men's testosterone gel; and the progesterone problem, in which the FDA-only framework leaves patients with no option except a pharmacologically distinct synthetic progestin when commercial dose ranges fall short.

The episode also goes into the regulatory reality of 503A and 503B compounding pharmacies, the neurosteroid pharmacology that makes progesterone and synthetic progestins non-interchangeable, and what individualized prescribing actually requires when a patient does not fit the commercial options.

The compounding debate does not have to stay murky. This is the clinical argument.

HRT University is a physiology-first clinical education program for licensed providers. Jointly accredited through Pinnacle Conference LLC (ACCME, ACPE, ANCC) for 30 CEUs.

Learn more about HRT University:https://bit.ly/4twBb0D

HRTU Newsletter:https://nicomislenp.kit.com/8050eeea5f

Join the HRT University Facebook Group:https://www.facebook.com/groups/1179376819949373/